Skip to main content

2022 AbbVie UK Golden Ticket in collaboration with We Are Pioneer Group (WAPG)

A programme offering a year of lab and office space at selected WAPG locations* across the UK.

Submit your application here www.wapg.link/AbbVie

All submissions must be received by 22nd May 2022 11:59pm BST. 

 

Programme Overview:

AbbVie is excited to launch the 2022 AbbVie UK Golden Ticket in collaboration with We Are Pioneer Group (WAPG), the UK’s largest ecosystem provider for science and innovation businesses, to support the thriving UK life sciences start-up community.

For AbbVie, this demonstrates our commitment to investing in the UK’s world class life sciences sector and accelerating the delivery of life-changing innovations to patients

The Golden Ticket programme awards one year of free-lab space, funded by AbbVie, and access to core facilities and services at selected WAPG locations*, membership to the WAPG community of scientists, technologists and entrepreneurs, and support from AbbVie’s world leading global scientists, business leaders and mentors.

AbbVie will grant one Golden Ticket to an early-stage UK life science biotech company in 2022.

* BioCity Glasgow, Wilton Centre (Redcar), BioCity Nottingham, Colworth Park (Bedfordshire), Kent Science Park.

 

Application Requirements:

AbbVie is looking for early-stage biotech companies that fit the following criteria:

  • Focused on science / technology with potential to generate transformational therapies in areas that align strategically with AbbVie’s therapeutic areas of interest (listed below)
  • Developing therapeutic platform technologies, including gene therapy, novel cell therapy, gene editing, or novel drug-discovery or platform technologies
  • Exclusions: Diagnostics, Devices, Research Tools, and Healthcare Services/IT

 


Additional Requirements:

  • Companies must have their principal place of business in the UK or be willing to relocate
  • Companies must not have a significant partnership with another large biopharmaceutical company. However, current or prior recipients of similar awards sponsored by other pharmaceutical companies or lab spaces are eligible to apply
  • Companies must meet Abbvie’s Golden Ticket criteria: 
    • Total equity funding raised must be less than £5M GBP before receiving the Golden Ticket
    • Companies must operate in the life sciences sector and have an impact on human health or therapeutic drug development
    • Companies must be financially and scientifically ready to move into a selected WAPG location* within two to six months of receiving the Abbvie Golden Ticket 

* BioCity Glasgow, Wilton Centre (Redcar), BioCity Nottingham, Colworth Park (Bedfordshire), Kent Science Park.

 

Details

How to Apply

Submit your application here www.wapg.link/AbbVie. Please note this link will take you to the We Are Pioneer Group Website which is not owned by AbbVie. 

All submissions must be received by 22nd May 2022 11:59pm BST. Applicants may only submit one entry each.

Please include the following in your application:

  • Name of company
  • Primary contact at company
  • Therapeutic area
  • One sentence summarizing the scientific basis of the programme/technology/asset
  • Funding to date: please include total funding received to date as well as the funder(s) and funding amount(s)
  • A high-resolution company logo (if applicable)
  • Non-confidential slide deck:
    • Applicants must provide a non-confidential slide deck of no more than 10 (ten) slides that emphasise:
      • Your company’s mission statement
      • Scientific founders, management team & expertise
      • The science behind the technology or asset
      • The prioritised and potentially applicable indications
      • Unique scientific value-add: What differentiates your technology or therapeutic from other companies in the competitive landscape?
      • Relevant IP and publications that include data supporting your science
      • Mitigation of risk: What are the potential pitfalls and key challenges?
      • Anticipated benefits of securing an AbbVie – WAPG Golden Ticket
      • Anticipated move-in date to a selected WAPG location
      • Company roadmap for upcoming key milestones (including financing)
      • Growth / research plan during the AbbVie Golden Ticket award one-year timeframe

Judging Criteria and Judges

AbbVie leaders who are qualified scientific experts in respective fields, including specialties in scientific and/or medical research and business, will review all submissions. The following criteria will form application judging criteria:

  • Fit relating to the research fields of oncology, immunology, neuroscience, or eye care. Judges will also consider novel target(s) identification, drug delivery, discovery technology platforms, and translational research and development.
  • Quality of the scientific data, research plan and/or technology platform
  • Potential to successfully achieve research milestones and programme development
  • Unmet need for the research in the relevant field. Is this research/programme/technology addressing a critical medical need?
  • Readiness to move into a selected We Are Pioneer Group location within two to six months of being selected for the award

Timelines

  • Application submission deadline: 22nd May 2022 at 11:59pm BST
  • Announcement of top 4-5 applications and final pitch dates will be in June 2022

FAQs

What is the AbbVie Golden Ticket – WAPG Award? 

The AbbVie Golden Ticket programme awards early-stage life science companies or biotech start-ups with one year free lab and office space at selected We Are Pioneer Group (WAPG) locations* for one year.   

The value of a Golden Ticket prepays the cost of one (1) lab bench, one (1) desk and WAPG membership for one (1) person for one (1) year. If no benches are available at the selected site the value of the Golden Ticket will be extended while the company remains on the waitlist for a bench. In addition recipeints receive access to core facilities and services at selected WAPG locations, membership to the WAPG community of scientists, technologists and entrepreneurs, and support from AbbVie’s world leading global scientists, business leaders and mentors.

The winner will receive priority admission or renewal for one year’s use of a lab bench and access to shared facilities at a selected WAPG location, as well as opportunities to engage with AbbVie scientific and business executives.

* BioCity Glasgow, Wilton Centre (Redcar), BioCity Nottingham, Colworth Park (Bedfordshire), Kent Science Park.
 

How do I know if I am eligible for a Golden Ticket?

Golden Tickets may be awarded to either startup companies that are interested in joining the WAPG Community or current Resident Companies.

To be eligible to participate to have the opportunity to receive the Award, the Applicant  must: (1) be an independent legal entity (SME); (2) not have raised more than £5M GBP before receiving the Golden Ticket; (3) submit a complete Application; (4) represent and warrant that the Applicant has read and agrees to abide by all requirements of these Rules; (5) not be affiliated with or employed by AbbVie or WAPG including as an employee, contractor, officer or director of AbbVie or WAPG and including as an immediate family member of AbbVie or WAPG (including parents, spouses, children, siblings or any individual residing in the household of a AbbVie, officer or director (whether or not related)); and (6) not be an academic institution such as a college, university or school.

Diagnostics, Devices, Research Tools, and Healthcare-Services & IT companies are excluded.

The 2022 AbbVie Golden Ticket winner will be chosen by a team of AbbVie’s scientific and business leaders and will be based on the strength and novelty of the scientific rationale, and the potential to transform patient care. 

When will I be able to use my Golden Ticket?

The top 4-5 proposals (semi-finalists) will be invited to a final pitch virtual presentation in June 2022.

Companies must be financially and scientifically ready to move into a selected WAPG location* within two to six months of receiving the ticket and to execute on the submitted research plan.

* BioCity Glasgow, Wilton Centre (Redcar), BioCity Nottingham, Colworth Park (Bedfordshire), Kent Science Park.
 

Where can I find more details on AbbVie’s areas of focus for external innovation?

Please refer to our Therapeutic Focus Areas: 

https://www.abbvie.co.uk/our-science/therapeutic-focus-areas.html 

For more information and to apply visit www.wapg.link/AbbVie. Please note this link will take you to the We Are Pioneer Group Website which is not owned by AbbVie.